title: Cyclosporine nanomicelle eye drop: a novel medication for corneal graft transplantation treatment.
abstract: Corneal transplantation has been used to treat severe eye disease for decades, but the therapeutic effect of the operation is highly compromised by immunological allograft rejection. To improve the success rate of corneal transplantation, we studied the protective effects of cyclosporine nanomicelle eye drops (CNED) on immune rejection after high-risk corneal transplantation and its underlying mechanisms. The therapeutic effects against immune rejection of both conventional cyclosporine eye drop (CCED) and CNED in different concentrations were assessed and compared using animal models of corneal transplantation. In addition, the expression of nuclear factor-κ-gene binding (NF-κB) as well as its target intracellular adhesion molecule 1 (ICAM-1) in the corneal samples obtained from recipients treated with either CCED or CNED was also screened. The results showed that the CNED displayed significantly better effects at suppressing the immune response induced by corneal transplantation compared to CCED. CNED also significantly down-regulated the NF-κB and ICAM-1 expressions, indicating NF-κB might play an important role in the initiation of an immune response against the allograft. Our study demonstrates CNED may suppress the NF-κB pathway to attenuate the immune response, which highlights the possible therapeutic applications of cyclosporine nanomicelle eye drops in corneal transplantation.
authors.affiliation: Department of Ophthalmology, Teaching Hospital, Ningbo University School of Medicine.
authors.forename: Hongkui
authors.initials: H
authors.lastname: Zhang
authors.forename: Ling
authors.initials: L
authors.lastname: Wang
authors.forename: Longlu
authors.initials: L
authors.lastname: Zhang
mesh_terms: D000818:Animals; D003315:Cornea / Q000601:surgery*; D016039:Corneal Transplantation; D016572:Cyclosporine / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use; D015536:Down-Regulation; D016503:Drug Delivery Systems; D006084:Graft Rejection / Q000378:metabolism / Q000517:prevention & control*; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D018799:Intercellular Adhesion Molecule-1 / Q000378:metabolism; D008297:Male; D008823:Micelles; D016328:NF-kappa B / Q000378:metabolism; D053758:Nanoparticles; D009883:Ophthalmic Solutions / Q000627:therapeutic use*; D017207:Rats, Sprague-Dawley; D017208:Rats, Wistar; D014184:Transplantation, Homologous
chemical_list: D007166:Immunosuppressive Agents; D008823:Micelles; D016328:NF-kappa B; D009883:Ophthalmic Solutions; D018799:Intercellular Adhesion Molecule-1; D016572:Cyclosporine